Skip to main content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology


04-06-2021 | EULAR 2021 | Conference coverage | Video

COSMOS: Further evidence for the benefits of guselkumab in PsA

Laura Coates outlines the findings from a phase 3b trial of guselkumab versus placebo in patients with psoriatic arthritis and an inadequate response to TNF inhibitors.

EULAR 2021 Virtual Congress coverage

Access news and expert commentary from the EULAR 2021 Virtual Congress.

MOST READ | COVID-19 & rheumatic disease

05-06-2021 | EULAR 2021 | Conference coverage | News

Pfizer–BioNTech vaccine immunogenicity confirmed in patients with AIIRDs

Research confirms immunogenicity with the Pfizer–BioNTech COVID-19 vaccine in most patients with autoimmune inflammatory rheumatic diseases.

MOST WATCHED | COVID-19 & rheumatic disease

02-06-2021 | EULAR 2021 | Conference coverage | Video

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

Jeffrey Sparks and Zachary Wallace talk about the potential for COVID-19 being more severe in rheumatoid arthritis patients treated with rituximab or JAK inhibitors rather than TNF inhibitors.

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

MOST READ | Inflammatory arthritis

04-06-2021 | EULAR 2021 | Conference coverage | News

KEEPsAKE 2 supports risankizumab for the treatment of PsA

The IL-23 inhibitor risankizumab is a promising treatment option for psoriatic arthritis, suggest results from the KEEPsAKE 2 trial presented at the EULAR 2021 Virtual Congress.

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

MOST READ | JAK inhibitors

07-06-2021 | EULAR 2021 | Conference coverage | News

Real-world studies point to similar effectiveness of JAK inhibitors and biologics

Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.


20-05-2021 | Systemic lupus erythematosus | News

RISE trial supports further investigation of dapirolizumab pegol for SLE

The addition of dapirolizumab pegol to standard therapy may warrant further investigation for the treatment of systemic lupus erythematosus, phase 2 trial results suggest.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox


Interviews with expert rheumatologists on patient care

Image Credits